- Home
- ESPR vs ALDX Comparison
ESPR vs ALDX Comparison
Compare ESPR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- ALDX
- Stock Information
- Founded
- ESPR 2008
- ALDX 2004
- Country
- ESPR United States
- ALDX United States
- Employees
- ESPR N/A
- ALDX N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- ALDX Health Care
- Exchange
- ESPR Nasdaq
- ALDX Nasdaq
- Market Cap
- ESPR 305.0M
- ALDX 304.9M
- IPO Year
- ESPR 2013
- ALDX 2014
- Fundamental
- Price
- ESPR $1.69
- ALDX $6.58
- Analyst Decision
- ESPR Buy
- ALDX Strong Buy
- Analyst Count
- ESPR 7
- ALDX 2
- Target Price
- ESPR $6.36
- ALDX $10.00
- AVG Volume (30 Days)
- ESPR 4.2M
- ALDX 666.8K
- Earning Date
- ESPR 03-04-2025
- ALDX 05-01-2025
- Dividend Yield
- ESPR N/A
- ALDX N/A
- EPS Growth
- ESPR N/A
- ALDX N/A
- EPS
- ESPR N/A
- ALDX N/A
- Revenue
- ESPR $332,314,000.00
- ALDX N/A
- Revenue This Year
- ESPR $5.51
- ALDX N/A
- Revenue Next Year
- ESPR $1.42
- ALDX N/A
- P/E Ratio
- ESPR N/A
- ALDX N/A
- Revenue Growth
- ESPR 185.66
- ALDX N/A
- 52 Week Low
- ESPR $1.47
- ALDX $2.75
- 52 Week High
- ESPR $3.94
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- ESPR 49.78
- ALDX 53.63
- Support Level
- ESPR $1.47
- ALDX $6.22
- Resistance Level
- ESPR $1.61
- ALDX $6.87
- Average True Range (ATR)
- ESPR 0.12
- ALDX 0.46
- MACD
- ESPR 0.02
- ALDX -0.03
- Stochastic Oscillator
- ESPR 56.41
- ALDX 60.51
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.